Lessons for the stem cell discourse from the gene therapy experience

Perspectives in Biology and Medicine

Volumn 48, Issue 4, 2005, Pages 585-591

  Friedmann, Theodore ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; EMBRYONIC STEM CELL; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; HEALTH CARE COST; HEALTH EDUCATION; HISTORY OF MEDICINE; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; STEM CELL TRANSPLANTATION;

EID: 26844465105     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2005.0089     Document Type: Review

References (23)

1. Blaese, R. M., et al. 1995. T-lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270:475-80.
2. Bordignon, C., et al. 1995. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470-75.
3. Friedmann T. 1994. The promise and over-promise of human gene therapy. Gene Therapy 1:217-18.
4. Friedmann, T. 1999. The origins, evolution and directions of human gene therapy. In The development of human gene therapy, ed. T. Friedmann, 1-20. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
5. Friedmann, T. 2003. The new era of human gene therapy research: A balance of unequivocal benefit and unequivocal harm. Mol They 8:5-7.
6. Friedmann, T., P. Noguchi, and C. Mickelson. 2001. Evolution of review and regulation in gene therapy. Curr Opin Biotechnol 12:304-11.
7. Friedmann, T., and R. Roblin. 1972. Gene therapy for human genetic disease. Science 175: 949-55.
8. Grossman, M., et al. 1995. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Med 1:1148-54.
9. Hacein-Bey-Abina, S., et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185-93.
10. Hacein-Bey-Abina, S., et al. 2003. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-56.
11. Hitt, M. M., R. J. Parks, and F. L. Graham. 1999. Structure and genetic organization of adenovirus vectors. In The development of human gene therapy, ed.T. Friedmann, 61-86. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
12. Knowles, M. R., et al. 1995. A controlled study of adenoviral-mediated gene transfer in nasal epithelium of patients with cystic fibrosis. N Engl J Med 333:823-31.
13. Orkin, S. H., and A. G. Motulsky. 1995. Report and recommendation of the panel to assess the NIH investment in research on gene therapy, http://www.nih.gov/news/ panelrep.html.
14. Raper, S. E., et al. 2003. Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148-58.
15. Rosenberg, S.A., et al. 1990. Gene transfer into humans: Immunotherapy of patients with melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570-78.
16. Samulski, R. J., S. Much, and N. Muzyczka. 1999. Adeno-associated viral vectors. In The development of human gene therapy, ed. T. Friedmann, 131-72. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
17. Shimotohno, K., and H. M. Temin. 1981. Formataion of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus. Cell 26:67-77.
18. Tabin, C. J., et al. 1982. Adaption of a retrovirus as a eukaryotic vector transmitting the herpes simplex thymidine kinase gene. Mol Cell Biol 2:426-36.
19. Varmus, H. 1995. NIH review of gene therapy protocols. Science 267:1889.
20. Vastag, B. 2004. Private efforts pick up stem cell slack. JAMA 291:2059-60.
21. Verma, I. 1994. Gene therapy: Hopes, hypes and hurdles. Mol Med 1:2-3.
22. Wei, C., et al. 1981. Construction and isolation of a transmissible retrovirus containing the src gene from Harvey murine sarcoma virus and the thymidine kinase gene from herpes simplex virus type 1. J Virol 39:935-44.
23. Willis, R. C., et al. 1984. Partial phenotypic correction of human Lesch-Nyhan (HPRT-deficient) lymphoblasts with a transmissible retroviral vector. J Biol Chem 259:7842-49.